01 · Label
Label review
Every SKU red-lined against CCR § 17400 et seq. with the subsection cited on every correction.
CCR 17400-series packaging and labeling, CCR 17408 recall procedures, claim substantiation, and the batch-record-to-label audit trail that DCC’s 2026 amendments now require.
A California cannabis label is not a design asset. It is a regulatory artifact governed by CCR Title 4 Division 19 Article 5 (§ 17400 et seq. for packaging and labeling), CCR § 15724 (the ±10% THC/CBD deviation tolerance between label and COA), the federal Poison Prevention Packaging Act standard at 16 CFR § 1700.1(b)(4) (the child-resistant packaging benchmark DCC adopts by reference), Business & Professions Code §§ 26120, 26121, and 26152.1 (the statutory backbone for packaging, label content, and vape-specific rules), and AB 1894’s vape-disposal labeling requirements that took effect in 2024. One SKU released with a self-generated METRC UID, a missing “Cannabis-Infused” statement, a non-DCC-issued universal symbol, or a per-package THC overage triggers an immediate distributor embargo, a Form DCC-LIC-017 corrective action plan, and a public Notice on the DCC compliance-action record.
Owning the work means four concrete things. We red-line every SKU against the primary-panel and information-panel rules — product identity, the DCC-issued universal symbol at minimum 0.5″×0.5″ in black, net weight in both metric and U.S. customary units, the ALL-CAPS bold government warning, the mg-per-serving and mg-per-package cannabinoid disclosures for edibles, the ±10% deviation check against the COA under CCR § 15724, and the “Cannabis-Infused” statement bold-and-larger than the product identity on every edible. We verify CRP mode (initial vs. lifetime, with the “not child-resistant after opening” statement on initial-CRP packages), tamper-evidence, opacity for edibles, resealability for multi-serving formats, and the prohibition on imitating products marketed to children. We draft the recall and corrective-action playbook against the BPC § 26131 framework and the DCC-approved CAP process, and we run a mock recall annually so a real one closes in hours. And we maintain an amendment-tracking monitor so the label library moves with DCC rulemaking — AB 1894 vape disposal language, the late-2025 allergen-disclosure guidance, and the post-April-2026 Schedule III warning-text watch.
What you keep: brand identity, design, product decisions, SKU strategy, creative direction, and the manufacturing run itself. Where the work crosses into privileged legal analysis — an Accusation under the DCC Disciplinary Guidelines, a trademark or trade-dress dispute over a Hershey-style chocolate or Skittle-style gummy, an FDA-adjacent regulatory challenge on a tincture positioned as supplement-adjacent — we coordinate with your retained counsel or introduce one from our cannabis-bar network. The service is compliance consulting on packaging, labeling, claims, and recall readiness; we do not practice law and we do not run analytical testing (that work sits with your DCC-licensed Type 8 Testing Laboratory).
Figures from the DCC Feb 5 2025 enforcement recap, CCR Title 4 Division 19 Article 5 (§ 17400 et seq. for packaging and labeling), CCR § 15724 (label-to-COA ±10% deviation tolerance), Business & Professions Code §§ 26120, 26121, 26152.1, and AB 1894 (vape-disposal labeling, effective 2024).
Every figure below is sourced to the DCC, the CCR, or published enforcement records. Each is a release-stopping finding a document-based release gate prevents.
A placeholder UID printed on the package because the METRC tag was not yet issued at print time. Immediate distributor embargo and a Form DCC-LIC-017 corrective action plan — one of the fastest paths from manufacturing line to public Notice on the DCC compliance-action record. (CCR § 17400 et seq.)
Label THC or CBD figure deviates by more than ±10% from the lab Certificate of Analysis. Distributor must hold and relabel before sale. The most common reason a finished batch sits at distribution while a relabel is staged. (CCR § 15724)
A multi-serving edible packaged in initial-CRP packaging instead of lifetime-CRP, or initial-CRP without the “not child-resistant after opening” statement. 16 CFR § 1700.1(b)(4) is the benchmark; opacity for edibles and resealability for multi-serving formats are sister rules with the same enforcement profile. (DCC packaging guidance)
Adult-use edible above 10 mg per serving or 100 mg per package, or a 100 mg bar that is one undivided block instead of ten distinguishable squares. Reformulate, rescore, or repackage — not a relabel. The most expensive failure mode on the list. (DCC Disciplinary Guidelines)
We close all four at the source. Every UID pulled live from METRC at print time, never typed. Every label THC and CBD figure reconciled against the COA inside the ±10% CCR § 15724 band before release. Every CRP mode confirmed against packaging cert with the “not child-resistant after opening” statement on initial-CRP SKUs. Every edible serving structure validated against the 10 mg/100 mg ceilings before the artwork goes to print. Release gates are document-based, not opinion-based.
Every SKU red-lined against CCR § 17400 et seq. with the subsection cited on every correction.
Every label THC/CBD figure reconciled against the COA inside the ±10% CCR § 15724 band.
Marketing claims reviewed for FTC substantiation and BPC § 26152 advertising rules; substantiation file built.
Government warning verified ALL-CAPS, bold, exact text. Vape, concentrate, allergen, and youth-appeal review staged.
CRP mode (initial vs. lifetime) verified against 16 CFR § 1700.1(b)(4); tamper-evidence and opacity confirmed.
BPC § 26131 recall SOP, DCC notification templates, mock-recall drill on a real SKU annually.
Shared-use kitchen and co-pack cross-contact documentation per DCC late-2025 allergen guidance.
Batch-to-label-to-METRC-UID trail meeting CCR § 15037 seven-year retention.
Incoming-material COA audit protocol; quarantine pathway for non-conforming lots before manufacturing release.
Labels updated as rules change — AB 1894 vape, post-Schedule-III warning watch, allergen guidance pipeline.
The red-lined labels are the visible artifact. The dividend is what happens the day a DCC inspector walks in, a distributor flags a batch at QA, or a buyer opens diligence on the brand — and every panel, every warning, every CRP mode, every UID is already anchored to a document.
When a designer asks why the government warning must be ALL-CAPS bold and 6 point minimum, we cite CCR § 17400 et seq. and the DCC labeling guidance. When a brand manager pushes back on a health-claim deletion, we cite FTC Section 5 substantiation doctrine and BPC § 26152 advertising restrictions. When a buyer asks for proof of child-resistance, we surface the packaging certification against the federal Poison Prevention Packaging Act standard at 16 CFR § 1700.1(b)(4). When the THC label figure is challenged, we surface the ±10% CCR § 15724 reconciliation worksheet. Every red-line the label library carries is anchored in a specific regulation section — not a stylistic preference.
California cannabis labeling sits inside a layered authority stack: CCR Title 4 Division 19 Article 5 (§ 17400 et seq. for packaging and labeling) plus CCR § 15724 (label-to-COA tolerance) and CCR § 15037 (seven-year recordkeeping); the federal CRP standard at 16 CFR § 1700.1(b)(4) adopted by reference; Business & Professions Code §§ 26120 (packaging), 26121 (label content), 26131 (recall and product safety), 26152 and 26152.1 (advertising and vape-specific advertising); AB 1894 (vape disposal labeling, 2024); FTC Section 5 substantiation doctrine where claims cross state lines digitally; and Form DCC-LIC-017 (the corrective action plan that becomes a regulatory commitment once filed). We track every layer simultaneously, plus every DCC rulemaking docket that amends them.
The universal symbol is the black triangle with an exclamation point, a cannabis leaf, and the letters “CA” beneath. It must appear on the primary panel, in black, at minimum 0.5″×0.5″. Only the exact DCC-issued asset is acceptable — no recolors, no white backgrounds, no third-party redraws. Designers regularly re-create the symbol from memory; QA must enforce use of the official file from the DCC packaging page.
Under CCR § 15724, the total THC or total CBD figure on the label may deviate up to ±10% from the value reported on the lab Certificate of Analysis. Anything outside that band requires a relabel before sale. In practice the distributor (Type 11) is the QA gatekeeper that catches this — distributors may apply final lab-result figures, but they may not remediate goods themselves; remediation requires a DCC-approved corrective action plan filed by the manufacturer.
AB 1894 (effective 2024) and BPC §§ 26120(f) and 26152.1 set vape-specific rules: the universal symbol must appear on the inner cartridge or device itself (not just the outer box); packaging and ads must clearly mention proper hazardous-waste disposal; and labeling cannot describe the device as “disposable,” “trash-ready,” or “recyclable.” Existing vape SKUs frequently fail on the “disposable” language alone — an audit of every vape SKU against AB 1894 is the first move.
Adult-use edibles are limited to 10 mg THC per serving and 100 mg per package; medicinal edibles are limited to 10 mg per serving and 2,000 mg per package. Adult-use non-edibles (tinctures, capsules, topicals) cap at 1,000 mg per package; medicinal non-edibles at 2,000 mg. Servings must be physically distinguishable — a 100 mg bar must split cleanly into ten 10 mg squares, not be a single block. Edibles must also demonstrate homogeneity at lab.
The federal benchmark is the Poison Prevention Packaging Act “special packaging” standard at 16 CFR § 1700.1(b)(4). Initial-CRP is allowed for flower, flower-only pre-rolls, inhaled concentrates, and single-serving products — but the package must carry the statement “This package is not child-resistant after opening.” Lifetime-CRP is required for multi-serving edibles, multi-serving concentrates, suppositories, and any package the consumer expects to access multiple servings from. Multi-serving formats must also be resealable in a way that maintains child-resistance.
The exact statutory text under BPC § 26121 must appear in ALL CAPS and bold: “GOVERNMENT WARNING: THIS PRODUCT CONTAINS CANNABIS, A SCHEDULE I CONTROLLED SUBSTANCE…” (continuing through the keep-out-of-reach, 21+, pregnancy/breastfeeding, and impaired-driving language). Paraphrasing, abbreviating, or dropping the bolding is one of the most common DCC findings. Note: as of April 2026 the federal rescheduling of state-licensed medical cannabis to Schedule III has not yet flowed through to a state-statute warning amendment — operators continue using the existing statement until DCC formally amends the rule.
Common food allergens (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, sesame) used in cannabis edibles must be disclosed FDA-style — either via a “Contains:” statement or via parenthetical in the ingredient list. DCC issued allergen guidance in late 2025 emphasizing operator understanding of how allergens may appear, and proactive allergen-control programs are now an inspection focus area. “May contain” hedges are not a substitute for specific declarations.
Yes — we work alongside your creative team. We provide compliance red-lines on marked-up PDFs with the regulation cited on every change; they own the design, brand voice, and art direction. Typical revision cycle is two rounds — initial red-line, designer revision, compliance verification, release. Where a creative decision conflicts with a compliance requirement, we write the conflict down with citations so the tradeoff is visible to brand leadership.
We build the BPC § 26131 recall SOP tailored to your distribution footprint, draft DCC and CDPH notification templates, file the Form DCC-LIC-017 corrective action plan, and run an annual mock drill on a real SKU from shelf to METRC destruction documentation. Hidden recalls — reworking product without DCC approval — are routinely caught and result in escalated discipline; the CAP process is mandatory. If a real recall triggers, we coordinate the DCC notification, the CDPH notification where applicable, the distributor and retailer pulls, and the METRC destruction event on a single timeline.
Standard engagement is $8,000–$35,000 depending on SKU count, product-category mix (edibles and vapes carry more rule surface area than flower or pre-rolls), and substantiation complexity. Ongoing amendment-tracking monitor adds $750–$1,500 per month. Urgent single-SKU red-line plus recall readiness is typically $3,000–$6,000 on a 72-hour timeline. Ongoing Compliance Retainer clients get label work at a reduced project rate.